Research programme: checkpoint kinase 2 inhibitors - Provid
Alternative Names: NSC-1095555; NSC-744039; PV-1019Latest Information Update: 16 Jul 2016
At a glance
- Originator Provid Pharmaceuticals
- Class Small molecules
- Mechanism of Action Checkpoint kinase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Solid-tumours in USA
- 15 Nov 2009 Pharmacodynamics data from in vitro studies in Solid tumours presented at the 21st AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2009)
- 15 Nov 2009 Preclinical trials in Solid tumours in USA (unspecified route)